Suppr超能文献

通过增殖细胞核抗原评分预测乳腺癌患者的早期复发和生存期缩短

Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score.

作者信息

Tahan S R, Neuberg D S, Dieffenbach A, Yacoub L

机构信息

Department of Pathology, New England Deaconess Hospital, Boston, MA 02215.

出版信息

Cancer. 1993 Jun 1;71(11):3552-9. doi: 10.1002/1097-0142(19930601)71:11<3552::aid-cncr2820711115>3.0.co;2-n.

Abstract

BACKGROUND

Cell cycle kinetic measures have been shown to have prognostic significance in breast cancer. Methods that have been used to assess the proliferating fraction of tumors include measurements of DNA content with S-phase calculation by flow cytometric analysis, radioisotope-labeled nucleotide incorporation, and cell cycle-associated protein expression. The recent discovery of the S-phase-specific nuclear protein proliferating cell nuclear antigen (PCNA) opens the door for a novel approach to cell kinetic measurement with an immunocytochemical assay.

METHODS

A quantitative immunocytochemical assay for PCNA was performed on 82 primary invasive breast carcinomas fixed in formaldehyde solution and embedded in paraffin and 18 corresponding axillary metastases. The percentage of tumor cells with strong nuclear staining was determined by visual count. This PCNA score was correlated with histologic parameters, age, relapse intervals, and long-term survival.

RESULTS

PCNA scores were distributed normally among primary carcinomas (range, 5-54; mean, 22.5). Carcinomas had much higher scores than adjacent normal epithelium (means, 22.5 and 4.1, respectively; P < 0.00001), and axillary node metastases had slightly higher scores than corresponding primary breast tumors (means 26.4 and 22.5, respectively; P = 0.05). The PCNA score did not correlate with age, tumor size, axillary node status, intramammary lymphatic-vascular invasion, or estrogen and progesterone binding capacities. Furthermore, its variability could not be explained by grade. PCNA values increased as the mitotic rate increased. Cancers with high PCNA scores (> or = 25) were associated with shorter disease-free (P = 0.007) and overall survival times (P = 0.01) than tumors with low PCNA scores (< 25) (median follow-up, 166 months).

CONCLUSIONS

PCNA score has potential value as a prognostic indicator in breast cancer. This method of assessing the proliferating pool offers advantages over other assays in terms of relative simplicity of the method, applicability to paraffin-embedded fixed tissue, and low cost.

摘要

背景

细胞周期动力学指标已被证明在乳腺癌中具有预后意义。用于评估肿瘤增殖分数的方法包括通过流式细胞术分析计算S期的DNA含量测量、放射性同位素标记核苷酸掺入以及细胞周期相关蛋白表达。最近发现的S期特异性核蛋白增殖细胞核抗原(PCNA)为通过免疫细胞化学测定进行细胞动力学测量的新方法打开了大门。

方法

对82例固定于甲醛溶液并石蜡包埋的原发性浸润性乳腺癌及18例相应的腋窝转移灶进行PCNA定量免疫细胞化学测定。通过视觉计数确定细胞核强染色的肿瘤细胞百分比。该PCNA评分与组织学参数、年龄、复发间隔和长期生存率相关。

结果

PCNA评分在原发性癌中呈正态分布(范围为5 - 54;平均值为22.5)。癌组织的评分远高于相邻正常上皮组织(平均值分别为22.5和4.1;P < 0.00001),腋窝淋巴结转移灶的评分略高于相应的原发性乳腺肿瘤(平均值分别为26.4和22.5;P = 0.05)。PCNA评分与年龄、肿瘤大小、腋窝淋巴结状态、乳腺内淋巴管侵犯或雌激素和孕激素结合能力无关。此外,其变异性无法用分级来解释。PCNA值随有丝分裂率增加而升高。PCNA评分高(≥25)的癌症与PCNA评分低(< 25)的肿瘤相比,无病生存期(P = 0.007)和总生存期(P = 0.01)更短(中位随访时间为166个月)。

结论

PCNA评分在乳腺癌中具有作为预后指标的潜在价值。这种评估增殖池的方法在方法相对简单、适用于石蜡包埋固定组织以及成本低方面比其他检测方法具有优势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验